hGBP-1 Expression Predicts Shorter Progression-Free Survival in Ovarian Cancers, While Contributing to Paclitaxel Resistance
| Autor: | Suzan Wadi, Deborah J. Vestal, Aaron R. Tipton, Jill A. Trendel, Sadik A. Khuder |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Programmed cell death endocrine system endocrine system diseases Paclitaxel Drug Resistance Drug resistance Guanylate-binding protein Article 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine medicine Progression-free survival TUBB3 GTPase Guanylate-Binding Protein business.industry medicine.disease female genital diseases and pregnancy complications 3. Good health Ovarian Cancer 030104 developmental biology chemistry Docetaxel 030220 oncology & carcinogenesis Ovarian cancer business medicine.drug |
| Zdroj: | Journal of cancer therapy |
| ISSN: | 2151-1934 |
| Popis: | Ovarian cancer is the gynecological cancer with the poorest prognosis. One significant reason is the development of resistance to the chemotherapeutic drugs used in its treatment. The large GTPase, hGBP-1, has been implicated in paclitaxel resistance in ovarian cell lines. Forced expression of hGBP-1 in SKOV3 ovarian cancer cells protects them from paclitaxel-induced cell death. However, prior to this study, nothing was known about whether hGBP-1 was expressed in ovarian tumors and whether its expression correlated with paclitaxel resistance. hGBP-1 is expressed in 17% of ovarian tumors from patients that have not yet received treatment. However, at least 80% of the ovarian tumors that recurred after therapies that included a tax-ane, either paclitaxel or docetaxel, were positive for hGBP-1. In addition, hGBP-1 expression predicts a significantly shorter progression-free survival in ovarian cancers. Based on these studies, hGBP-1 could prove to be a potential biomarker for paclitaxel resistance in ovarian cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|